HTG Molecular Diagnostics, Inc. provided revenue guidance for full year 2022. For the period, total revenue is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of total revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0025 USD | 0.00% | 0.00% | +92.31% |
2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+92.31% | 5.54K | |
-20.29% | 18.19B | |
-43.89% | 2.77B | |
+23.49% | 1.96B | |
-3.70% | 1.61B | |
+31.11% | 1.31B | |
-16.85% | 960M | |
-23.12% | 881M | |
+5.45% | 809M | |
+24.76% | 590M |
- Stock Market
- Equities
- HTGMQ Stock
- News HTG Molecular Diagnostics, Inc.
- HTG Molecular Diagnostics, Inc. Provides Revenue Guidance for Full Year 2022